Jim Cramer on SELLAS: “It’s a Great Spec”

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was one of the stocks on Jim Cramer’s radar on Mad Money as he explained that many investors might be missing out on the market’s biggest winners. Responding to a caller’s question about the company, Cramer stated:

Oh, this life science company that is, look, okay, so this is a good example. This stock’s up a great deal, alright? And you know, it’s losing a little money. It’s a great spec, and even though it’s up, I used to say, you know, I can’t touch it. I used to say that. I can’t do that right now, I can’t. I’m going to say two thumbs up or whatever to SLS. It. It’s that kind of market.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is a clinical-stage company focused on creating new treatments for cancer, specifically targeting the disease with its main product candidates, galinpepimut-S and SLS009. To advance these treatments forward, the company partners with major names like Merck, GenFleet Therapeutics, and Memorial Sloan Kettering Cancer Center for clinical trials and development.

While we acknowledge the risk and potential of SLS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SLS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1